Purpose: This study compared health care resource utilization (HCRU), costs, and persistence among patients newly diagnosed as having nonvalvular atrial fibrillation (NVAF) and newly treated with dabigatran versus warfarin.
INTRODUCTION
Atrial fibrillation (AF) is the most common clinical arrhythmia and a major cause of stroke. In the United States alone, an estimated 1 in 4 adults 40 years and older will develop AF during their lifetime, 1 placing them at 4-to 5-fold higher risk of stroke. 2 Strokes attributable to AF are associated with greater mortality, morbidity, and risk of recurrence than non-AF strokes. 3 The annual incremental cost of AF in the United States is estimated at $8705 per patient (2008 US dollars), reflecting greater use of both inpatient and outpatient services. 4 Extrapolated to the 2010 US population, the national incremental burden attributable to AF is in the range of $6 billion to $21 billion annually (2008 US dollars). 4 Warfarin, a vitamin K antagonist, is an oral anticoagulant (OAC) effective in reducing stroke risk in patients with AF. 5 However, warfarin has a narrow therapeutic range, requiring regular blood monitoring and dose adjustments to maintain the target international normalized ratio (INR) within 2.0 to 3.0. 6 US patients with AF maintain an INR within the therapeutic range a mean of 55% of the time. 7 Underanticoagulation, as evidenced by an INR o2.0, increases the risk and severity of ischemic stroke, 8, 9 whereas overanticoagulation (INR 43.0) increases bleeding risk. 9 There are considerable drug and food interactions with warfarin, 10 which can also compromise INR control. Both INR testing and the consequences of poor INR control consume considerable health care resources. [11] [12] [13] Dabigatran, 14 a direct thrombin inhibitor, is an OAC approved by the Food and Drug Administration in the United States in October 2010 to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF), which represents approximately 95% of AF cases. 15 Dabigatran offers several advantages over warfarin. First, INR testing is not required to maintain therapeutic levels. Next, in the pivotal Randomized Evaluation of Long-Term Anticoagulant Therapy clinical trial, dabigatran was associated with lower rates of stroke and systemic embolism compared with adjusted-dose warfarin. 16 Furthermore, in real-world clinical practice, patients newly diagnosed as having NVAF who initiate OAC therapy with dabigatran were more likely to persist with therapy than their counterparts initiating warfarin therapy. 17 However, the effect of these clinical advantages of dabigatran over warfarin on health care resource utilization (HCRU) in clinical practice has not been well characterized. The objective of this study was to compare real-world HCRU and costs among patients newly diagnosed as having NVAF who were newly treated with dabigatran versus warfarin. We also evaluated persistence to each OAC therapy during the first year of treatment.
METHODS Study Design and Data Source
This retrospective claims-based study used medical, pharmacy, and enrollment data from a large US managed care organization affiliated with Optum, Inc. The patient index date was identified based on the date of initiation of dabigatran or warfarin treatment. Because dabigatran was approved in October 2010, the patient identification period began on October 1, 2010 continuing through October 31, 2011. Data extracted for each patient covered 12 months before the index date and up to 12 months after the index date; therefore, the full study period spanned October 1, 2009 through October 31, 2012 ( Figure 1 ). During the patient identification period, the database contained 15,316,248 commercial and Medicare Advantage Prescription Drug coverage enrollees with medical and pharmacy benefits. Medical claims data used for this study included International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis and procedure codes, Healthcare Common Procedure Coding System codes, revenue codes, and paid amounts (combined health plan plus patient paid amounts). Pharmacy claims data used for this study included National Drug Codes for filled prescriptions, days supplied, quantity of drug supplied, and paid amounts. All study data were accessed using techniques compliant with the Health Insurance Portability and Accountability Act.
Patient Identification and Study Cohorts
The study sample comprised patients newly diagnosed as having NVAF and newly treated with dabigatran or warfarin. The index date was defined as the first pharmacy claim for dabigatran or warfarin (index OAC) during the patient identification period.
Patients were identified for inclusion in the study in a sequential manner. First, all patients were required to have Z1 inpatient claim (ie, medical claim associated with inpatient stay) or Z2 office visit or emergency department (ED) claims (ie, medical claims associated with office or ED visits or a combination thereof) with a diagnosis code for AF (ICD-9-CM code 427.31 in any position) in the 12 months before the index date. 4, [17] [18] [19] Patients were also required to have continuous health plan enrollment with medical and pharmacy benefits for 12 months before the index date (defined as the preindex period) and up to 12 months after (and including) the index date (defined as the follow-up period). End of follow-up was defined as the earliest of health plan disenrollment, medication discontinuation (or switch) from the index OAC, death, 12 months after the index date, or end of study period (October 31, 2012). The earliest medical claim with diagnosis code for AF during the preindex period was defined as the first AF claim. To distinguish NVAF from AF, patients with Z1 medical claim with evidence of valvular heart disease (Supplemental Table I ) were excluded. In the interest of excluding transient and secondary NVAF, patients with Z1 medical claim with evidence of cardiac surgery, myocarditis, pericarditis, or pulmonary embolism (Supplemental Table I ) within 30 days before the first AF claim were excluded. In addition, patients o18 years old on the index date and patients with Z1 medical claim with evidence of hyperthyroidism (Supplemental Table I ) during the preindex period were excluded. The remaining patients were then required to have Z2 pharmacy claims on separate dates for the index OAC (dabigatran or warfarin) during the follow-up period, including the pharmacy claim for the OAC on the index date.
Finally, the criteria of newly diagnosed NVAF and newly treated with dabigatran or warfarin were applied: newly diagnosed NVAF was defined as the occurrence of first AF claim within 30 days before the index date; patients with claim(s) for AF that occurred before 30 days from the index date (ie, days 31-365 before the index date) were excluded. Newly treated was defined as no pharmacy claims for any OAC (dabigatran, rivaroxaban, or warfarin) during the preindex period. Patients were then assigned to either the dabigatran or warfarin cohort according to the index OAC.
Patient Characteristics
Age, sex, geographic location, and health plan type (commercial or Medicare Advantage Prescription Drug coverage) were reported as of the index date. The following clinical indexes were calculated during the preindex period: Deyo-Charlson comorbidity score, 20 23 The Deyo-Charlson comorbidity score is a predictor of mortality risk defined by 17 medical conditions. The CHADS 2 score is a predictor of stroke risk that incorporates patient age (474 years) and history of chronic heart failure, hypertension, diabetes mellitus, and stroke/transient ischemic attack as risk factors; the CHA 2 DS 2 -VASc score includes 3 additional risk factors (female sex, age 65-74 years, and vascular disease). The HEMORR 2 HAGES score is a predictor of bleeding risk according to patient age (475 years), medical history (hepatic or renal disease, alcohol abuse, malignant tumor, reduced platelet count or dysfunction, rebleeding risk, uncontrolled hypertension, anemia, stroke), genetic factors, and excessive fall risk. The presence or absence of clinically relevant conditions or events during the preindex period was identified based on ICD-9-CM diagnosis and procedure codes from preindex medical claims (Supplemental Table I ). Preindex medication use was determined by pharmacy and medical claims and categorized as the presence or absence of any medication and as counts of individual medications or medication classes (Supplemental Table II ). Health care costs (ie, medical and pharmacy) were calculated for the preindex period. All-cause total health care costs represented the sum of medical and pharmacy costs; all costs were inflation adjusted to 2012 US dollars. 24 
Outcomes
Persistence to index OAC represented the time to discontinuation or switch of index OAC. Discontinuation was defined as failure to refill (ie, an absence of a pharmacy claim for the index exposure within 30 days [permissible gap] of the run-out date of the previous claim for the index exposure). Patients who did not discontinue or switch index OAC were right-censored at the earliest of: health plan disenrollment, death, end of 12-month follow-up, or end of study period (October 31, 2012). Although warfarin treatment discontinuation has been previously defined by gaps in both prescription fill dates and INR testing, 25 ,26 a 30-day medication gap is a sensitive measure of discontinuation.
17
Both HCRU and costs were calculated for the follow-up period and censored on the date of discontinuation or switch of index OAC (if either occurred). Because of variable length follow-up, HCRU and costs were reported as per-patient-permonth (PPPM). All-cause HCRU was defined as the counts of health care encounters, categorized as inpatient stay, ED visit, outpatient visit, and office visit. All-cause health care costs were calculated as total costs (sum of medical and pharmacy costs), medical costs, and pharmacy costs; all costs were inflation adjusted to 2012 US dollars. 24 
Propensity Score Matching
Patients in the dabigatran and warfarin cohorts were 1:1 nearest neighbor matched using propensity score matching (PSM) with a caliper of 0.2 of the SD of the estimated logit. Propensity scores were calculated by logistic regression modeling with the following predictor variables: age, sex, health plan type, geographic location, and index month and preindex characteristics, namely, Deyo-Charlson comorbidity score, CHADS 2 score, HEMORR 2 HAGES score, presence or absence of comorbidities (Supplemental Table I ), all-cause medical costs, all-cause pharmacy costs, index prescriber specialty, time from first AF claim to index date, and presence or absence of medication use (Supplemental Table II ).
Statistical Analysis
Between-cohort comparisons of pre-PSM, preindex characteristics were conducted with 2-sample t tests with Satterthwaite adjustment where appropriate (continuous variables) and χ 2 tests (categorical variables). Between-cohort comparisons of post-PSM, preindex characteristics and outcomes during followup were conducted with paired t tests (continuous variables) and Rao-Scott tests (categorical variables). Multivariable regression models adjusting for preindex characteristics were constructed to examine cohort differences in follow-up all-cause health care costs and time to index therapy discontinuation or switch. Time to index therapy discontinuation was modeled with Cox proportional hazards. The estimated time to therapy discontinuation was also described graphically using the Kaplan-Meier estimator of the cumulative hazard rate. All-cause total health care, medical, and pharmacy costs were modeled with Lin's regression, 27 ,28 which accounts for censored follow-up time and cost accumulation at multiple intervals. With this method, the follow-up period is partitioned into twelve 30-day intervals during which costs are accumulated and the cost within each 30-day interval is weighted by the probability of survival during each interval. The SEs for 12-month adjusted costs are based on 1000 bootstrapped samples.
All regression models included index OAC and the following adjustment variables: age, sex, geographic location, health plan type, presence or absence of preindex stroke, Deyo-Charlson comorbidity score, CHA 2 DS 2 -VASc score, HEMORR 2 HAGES score, and log-transformed preindex all-cause total health care costs. In addition, other covariates serving as adjustment variables only were included based on stepwise selection using P = 0.05 for both entry and retention in the model. Adjustment variables subject to stepwise selection were index prescriber specialty (cardiology or other) and the following preindex characteristics: presence or absence of selected comorbid conditions (cancer, rheumatoid arthritis, multiple sclerosis, coronary artery disease, acute myocardial infarction, cardiomyopathy, transient ischemic attack, ischemic stroke, heart failure, atrial flutter, hypertension, peripheral artery disease, liver disease, renal disease, chronic obstructive pulmonary disease or emphysema, hypothyroidism, diabetes, peptic ulcer or gastroesophageal reflux disease, venous thromboembolism, hyperlipidemia, Human Immunodeficiency Virus (HIV) infection, bone marrow disease, coagulopathy, dyspepsia, bleeding), the count of concomitant medication classes, pharmacy claims, all-cause outpatient visits, all-cause office visits, all-cause ED visits, and total length (days) of all inpatient stays.
RESULTS

Patient Identification and Characteristics
A total of 49,448 patients with NVAF and Z2 claims for either dabigatran (7013 patients) or warfarin (42,435 patients) on or after the index date were identified ( Figure 2 ). Among these patients, 1010 were newly diagnosed as having NVAF and newly treated with dabigatran, and 3200 were newly diagnosed as having NVAF and newly treated with warfarin. After PSM, 869 patients in each cohort were retained.
The pre-and post-PSM characteristics of each cohort for key matching variables are given in Table I ; the full complement of matching variables and other characteristics of interest are given in Supplemental  Table III . Among all matched patients, the mean age was 67.8 years, 40.4% were female, and most patients (64.7%) had commercial insurance. The mean time from first AF claim to index date was just 41 week and similar between cohorts (8.7 and 8.4 days for dabigatran and warfarin, respectively; P¼0.343). The mean Deyo-Charlson, CHADS 2, CHA 2 DS 2 -VASc, and HEMORR 2 HAGES scores were also similar between cohorts. After matching, clinical characteristics were similar between cohorts for all matched variables with the exception of preindex bleeding. Compared with the warfarin cohort, a slightly higher proportion of dabigatran-treated patients had preindex bleeding (6.2% vs. 4.0%, P ¼ 0.037).
HCRU and Costs
All-cause HCRU (PPPM) of the dabigatran and warfarin cohorts during follow-up is given in Table II. The dabigatran cohort had significantly fewer ED visits (0.10 vs 0.13, P ¼ 0.010), office visits (1.98 vs 2.96, P o 0.001), and outpatient visits (1.05 vs 1.48, P o 0.001) than the warfarin cohort. The mean counts of inpatient stays were lower for the dabigatran cohort, but the difference was not statistically significant between cohorts (P ¼ 0.093).
Adjusted 12-month, mean all-cause health care costs are presented in Table III . Similar to the unadjusted cost results, although pharmacy costs were higher for the dabigatran cohort (P o 0.001), total health care (P ¼ 0.318) and medical (P ¼ 0.750) costs were similar for both cohorts.
Persistence
Measures of persistence with index OAC are given in Table IV and Figure 3 . Compared with the warfarin cohort, a lesser proportion of patients in the dabigatran cohort discontinued therapy (51.9% vs 61.6%, P o 0.001), and dabigatran-treated patients continued to receive therapy longer (median days, 204.0 vs 161.0; mean days, 213.7 vs 195.5; P ¼ 0.001). The KaplanMeier probabilities of persistence were greater for the dabigatran cohort throughout the 365-day follow-up period (P o 0.001). In the adjusted Cox proportional hazards analysis, the dabigatran cohort had 21.5% lower risk of treatment discontinuation (hazard ratio, 0.785; 95% CI, 0.692-0.890; P o 0.001).
DISCUSSION
Our results provide important insights into the realworld HCRU and costs of patients newly diagnosed as having NVAF who are newly treated with dabigatran versus warfarin. Patients newly treated with dabigatran had less all-cause HCRU than patients taking warfarin. Patients initiating OAC therapy with dabigatran were also more likely to be persistent with therapy in the first year of treatment than those patients taking warfarin.
Patients newly treated with dabigatran had lower mean all-cause HCRU in the ambulatory setting than warfarin-treated patients. The dabigatran cohort incurred a mean of 33% fewer office and 29% fewer outpatient visits. Higher ambulatory service utilization among warfarin-treated patients likely reflects in part the incremental burden of regular INR testing and dose adjustments for patients managed with warfarin. A recent study of 5 US claims databases indicated that † Newly diagnosed NVAF was defined as the occurrence of the first AF claim within 30 days before the index date, and newly treated was defined as no claims for oral anticoagulant (dabigatran, rivaroxaban, or warfarin) during the 12-month preindex period. our results are based on all-cause utilization, and we cannot ascribe the overall higher HCRU in the warfarin cohort to specific events, such as INR testing, stroke, or bleeding. As expected, all-cause pharmacy costs were higher for the dabigatran cohort, given that dabigatran is available as a branded medication. However, all-cause total health care and medical costs were similar for both treatment cohorts, suggesting that dabigatran is a cost-neutral alternative to warfarin. According to the Cox proportional hazards analysis, patients taking dabigatran were 21.5% less likely to discontinue or switch therapy than warfarin-treated patients. The Kaplan-Meier probabilities of patients remaining on therapy at 1 year were 43.4% for the dabigatran cohort and 33.0% for the warfarin cohort. Given that dabigatran is a relatively new option in anticoagulation, there are limited comparator studies based on large claims databases in the peer-reviewed literature. 17, 31 Our results can be most readily compared with the findings of Zalesak et al, 17 whose study methods most closely resembled what we used to create newly diagnosed and newly treated NVAF cohorts and to define persistence. In the study by Zalesak et al, 17 1-year persistence was 50.3% for dabigatran versus 24.1% warfarin. Dabigatran persistence was somewhat higher than we observed, which may be partially a function of differences in patient preindex characteristics between the 2 studies. For 
Study Limitations
Certain limitations that are inherent to claimsbased analyses should be considered when interpreting the results of this study. The entire medical history of a patient is not available in claims databases, and the information that was captured in this study was limited to the study period. The presence of a diagnostic code on a medical claim is not proof positive of the presence of disease. To strengthen the selection of patients with evidence of AF, we required either an inpatient claim or Z2 office or ED claims with diagnosis code for AF. We used PSM to maximize the balance in relevant patient characteristics between the dabigatran and warfarin cohorts; however, there may have been other unmeasured or unidentified factors that were not balanced among cohorts and could have influenced the outcomes. Unlike dabigatran, warfarin use may be subject to frequent dose adjustments based on INR test results, which may shorten or lengthen the duration of medication supply available in a single prescription fill. Our estimates of persistence are based on the earliest gap in index OAC supply 430 days. It is possible that persistence was overestimated or underestimated using this technique; however, previous research has found that 89% of warfarin and 95% of dabigatran medication gaps were o30 days 17 ; thus, we would expect the degree of overestimation and underestimation to be similar between cohorts. Furthermore, pharmacy claims do not indicate whether the medication was taken or taken as prescribed. Finally, our results are based on patients with commercial or Medicare fee-for-service insurance and may not be generalizable to other populations.
CONCLUSIONS
Among patients newly diagnosed as having NVAF and newly treated with dabigatran or warfarin, those treated with dabigatran had significantly fewer office, outpatient, and ED visits than those taking warfarin. The all-cause total health care costs were similar among dabigatran-and warfarin-treated patients. Dabigatrantreated patients were also more likely to remain persistent and to do so for longer periods than warfarintreated patients during the first year of treatment.
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